Plus therapeutics introduces reyobiq™, fda-accepted proprietary name for lead drug candidate

Reyobiq™ (rhenium re186 obisbemeda) continues to be under clinical investigation for leptomeningeal metastases (lm) and recurrent glioblastoma (gbm) houston, march 20, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announces the u.s. food and drug administration (fda) has conditionally accepted the company's new proprietary name, reyobiq™, for its lead therapeutic candidate. a request for proprietary name review for reyobiq™ must be submitted once the marketing application (nda) is submitted.
PSTV Ratings Summary
PSTV Quant Ranking